Articles
Media
Eyeviews
Insights
Medical World News
Podcasts
Rapid Readouts
Viewpoints
Publications
Digital Edition
Supplements And Featured Publications
Conferences
Conference Listing
CME/CE
Resources
Sponsored
Zeiss Case Studies
Zeiss Cataract Insights
Zeiss Cataract Digitalization
Enhancing the Patient Journey
Between the Lines
Subscribe
Choose Specialty
AMD
Cataract & Refractive
Cornea
Gene Therapy
Glaucoma
Inflammation & Infection
Paediatrics
Retina
Spotlight -
Carl Zeiss Case of the Month
High-Frequency Deep Sclerotomy
iCare COMPASS Automated Perimeter
Choose Specialty
AMD
Cataract & Refractive
Cornea
Gene Therapy
Glaucoma
Inflammation & Infection
Paediatrics
Retina
Spotlight
Articles
Media
Publications
Conferences
CME/CE
Resources
Subscribe
Advertisement
EYLEA 8mg for the treatment of neovascular age-related macular degeneration and diabetic macular edema
home
/
video-series
/
eylea-8mg-for-the-treatment-of-neovascular-age-related-macular-degeneration-and-diabetic-macular
EP. 1: EYLEA’s unique MoA: What is the rationale for the higher molar dose?
Professor Jean-Francois Korobelnik, University Hospital of Bordeaux, France
January 23rd 2025
